Mesa Laboratories Net Worth
Mesa Laboratories Net Worth Breakdown | MLAB |
Mesa Laboratories Net Worth Analysis
Mesa Laboratories' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mesa Laboratories' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mesa Laboratories' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mesa Laboratories' net worth analysis. One common approach is to calculate Mesa Laboratories' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mesa Laboratories' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mesa Laboratories' net worth. This approach calculates the present value of Mesa Laboratories' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mesa Laboratories' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mesa Laboratories' net worth. This involves comparing Mesa Laboratories' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mesa Laboratories' net worth relative to its peers.
Enterprise Value |
|
To determine if Mesa Laboratories is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mesa Laboratories' net worth research are outlined below:
| The company reported the previous year's revenue of 216.19 M. Net Loss for the year was (254.25 M) with profit before overhead, payroll, taxes, and interest of 151.48 M. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Calculating The Intrinsic Value Of Mesa Laboratories, Inc. |
Mesa Laboratories Quarterly Good Will |
|
Mesa Laboratories uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mesa Laboratories. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mesa Laboratories' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of February 2024 Upcoming Quarterly Report | View | |
| 23rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 23rd of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Mesa Laboratories Target Price Consensus
Mesa target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Mesa Laboratories' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Buy |
Most Mesa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Mesa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Mesa Laboratories, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMesa Laboratories Target Price Projection
Mesa Laboratories' current and average target prices are 144.07 and 133.33, respectively. The current price of Mesa Laboratories is the price at which Mesa Laboratories is currently trading. On the other hand, Mesa Laboratories' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Mesa Laboratories Market Quote on 26th of February 2025
Target Price
Analyst Consensus On Mesa Laboratories Target Price
Know Mesa Laboratories' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mesa Laboratories is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mesa Laboratories backward and forwards among themselves. Mesa Laboratories' institutional investor refers to the entity that pools money to purchase Mesa Laboratories' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 124.4 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 113.8 K | Northern Trust Corp | 2024-12-31 | 93.8 K | Hhg Plc | 2024-12-31 | 86.3 K | Raymond James & Associates | 2024-09-30 | 76.9 K | Bank Of America Corp | 2024-12-31 | 68.5 K | Acadian Asset Management Llc | 2024-12-31 | 68.1 K | Kennedy Capital Management Inc | 2024-09-30 | 65.9 K | Charles Schwab Investment Management Inc | 2024-12-31 | 62.6 K | Blackrock Inc | 2024-12-31 | 844.4 K | Conestoga Capital Advisors, Llc | 2024-12-31 | 573 K |
Follow Mesa Laboratories' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 784.4 M.Market Cap |
|
Project Mesa Laboratories' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.91) | (1.82) | |
| Return On Capital Employed | (0.78) | (0.74) | |
| Return On Assets | (0.65) | (0.62) | |
| Return On Equity | (2.01) | (1.91) |
When accessing Mesa Laboratories' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mesa Laboratories' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mesa Laboratories' profitability and make more informed investment decisions.
Please note, the presentation of Mesa Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mesa Laboratories' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mesa Laboratories' management manipulating its earnings.
Evaluate Mesa Laboratories' management efficiency
Mesa Laboratories has return on total asset (ROA) of 0.0218 % which means that it generated a profit of $0.0218 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8938) %, meaning that it created substantial loss on money invested by shareholders. Mesa Laboratories' management efficiency ratios could be used to measure how well Mesa Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -1.82. The current year's Return On Capital Employed is expected to grow to -0.74. At present, Mesa Laboratories' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 407.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 947.2 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 24.30 | 12.43 | |
| Tangible Book Value Per Share | (31.70) | (30.11) | |
| Enterprise Value Over EBITDA | (3.04) | (2.89) | |
| Price Book Value Ratio | 3.73 | 2.35 | |
| Enterprise Value Multiple | (3.04) | (2.89) | |
| Price Fair Value | 3.73 | 2.35 | |
| Enterprise Value | 537.6 M | 564.5 M |
Evaluating the management effectiveness of Mesa Laboratories allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Mesa Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 4.0884 | Revenue | Quarterly Revenue Growth 0.175 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mesa Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mesa Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mesa Laboratories insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mesa Laboratories Corporate Filings
8K | 4th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 28th of January 2025 Other Reports | ViewVerify | |
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 15th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
Mesa Laboratories Earnings Estimation Breakdown
The calculation of Mesa Laboratories' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Mesa Laboratories is estimated to be 1.81125 with the future projection ranging from a low of 1.7625 to a high of 1.86. Please be aware that this consensus of annual earnings estimates for Mesa Laboratories is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.76 Lowest | Expected EPS | 1.86 Highest |
Mesa Laboratories Earnings Projection Consensus
Suppose the current estimates of Mesa Laboratories' value are higher than the current market price of the Mesa Laboratories stock. In this case, investors may conclude that Mesa Laboratories is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Mesa Laboratories' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 4 | 21.98% | 0.7918 | 1.81125 | -46.32 |
Mesa Laboratories Earnings History
Earnings estimate consensus by Mesa Laboratories analysts from Wall Street is used by the market to judge Mesa Laboratories' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Mesa Laboratories' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Mesa Laboratories Quarterly Gross Profit |
|
Mesa Laboratories Earnings per Share Projection vs Actual
Actual Earning per Share of Mesa Laboratories refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Mesa Laboratories predict the company's earnings will be in the future. The higher the earnings per share of Mesa Laboratories, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Mesa Laboratories Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Mesa Laboratories, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Mesa Laboratories should always be considered in relation to other companies to make a more educated investment decision.Mesa Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Mesa Laboratories' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-03 | 2024-12-31 | 1.51 | 0.7918 | -0.7182 | 47 | ||
2024-11-04 | 2024-09-30 | 1.38 | 0.63 | -0.75 | 54 | ||
2024-08-05 | 2024-06-30 | 0.44 | 0.84 | 0.4 | 90 | ||
2024-05-31 | 2024-03-31 | -0.11 | 3.7 | 3.81 | 3463 | ||
2024-02-05 | 2023-12-31 | 0.19 | 0.39 | 0.2 | 105 | ||
2023-11-06 | 2023-09-30 | 0.16 | -0.23 | -0.39 | 243 | ||
2023-08-03 | 2023-06-30 | -0.02 | -0.1 | -0.08 | 400 | ||
2023-05-25 | 2023-03-31 | 0.37 | 0.11 | -0.26 | 70 | ||
2023-02-06 | 2022-12-31 | 0.14 | 0.08 | -0.06 | 42 | ||
2022-11-03 | 2022-09-30 | -0.31 | 0.24 | 0.55 | 177 | ||
2022-08-04 | 2022-06-30 | 1 | -0.27 | -1.27 | 127 | ||
2022-05-31 | 2022-03-31 | 0.48 | -0.34 | -0.82 | 170 | ||
2022-02-03 | 2021-12-31 | 0.42 | 0.61 | 0.19 | 45 | ||
2021-11-04 | 2021-09-30 | 0.42 | 0.7 | 0.28 | 66 | ||
2021-08-05 | 2021-06-30 | 0.1 | 0.38 | 0.28 | 280 | ||
2021-06-01 | 2021-03-31 | 0.26 | 0.74 | 0.48 | 184 | ||
2021-02-03 | 2020-12-31 | 0.33 | -0.89 | -1.22 | 369 | ||
2020-11-05 | 2020-09-30 | 0.06 | 0.51 | 0.45 | 750 | ||
2020-08-06 | 2020-06-30 | 0.76 | 0.22 | -0.54 | 71 | ||
2020-06-01 | 2020-03-31 | 0.21 | 0.06 | -0.15 | 71 | ||
2020-02-10 | 2019-12-31 | 1 | -1.06 | -2.06 | 206 | ||
2019-11-06 | 2019-09-30 | 0.81 | 0.71 | -0.1 | 12 | ||
2019-07-30 | 2019-06-30 | 0.85 | 1.13 | 0.28 | 32 | ||
2019-06-03 | 2019-03-31 | 1.08 | 0.34 | -0.74 | 68 | ||
2019-02-04 | 2018-12-31 | 0.8 | 1.03 | 0.23 | 28 | ||
2018-10-31 | 2018-09-30 | 0.73 | 0.87 | 0.14 | 19 | ||
2018-07-31 | 2018-06-30 | 0.79 | 1.06 | 0.27 | 34 | ||
2018-06-05 | 2018-03-31 | 0.84 | 1.08 | 0.24 | 28 | ||
2018-02-05 | 2017-12-31 | 0.93 | 0.72 | -0.21 | 22 | ||
2017-11-06 | 2017-09-30 | 0.64 | 0.6 | -0.04 | 6 | ||
2017-07-31 | 2017-06-30 | 0.56 | 0.39 | -0.17 | 30 | ||
2017-06-07 | 2017-03-31 | 1 | 0.94 | -0.06 | 6 | ||
2017-02-02 | 2016-12-31 | 0.62 | 0.84 | 0.22 | 35 | ||
2016-11-02 | 2016-09-30 | 0.85 | 0.62 | -0.23 | 27 | ||
2016-07-28 | 2016-06-30 | 0.93 | 0.51 | -0.42 | 45 | ||
2016-06-02 | 2016-03-31 | 0.94 | 1.06 | 0.12 | 12 | ||
2016-02-02 | 2015-12-31 | 0.95 | 0.63 | -0.32 | 33 | ||
2015-11-02 | 2015-09-30 | 1.03 | 0.76 | -0.27 | 26 | ||
2015-08-03 | 2015-06-30 | 0.83 | 0.63 | -0.2 | 24 | ||
2015-06-01 | 2015-03-31 | 0.91 | 0.61 | -0.3 | 32 | ||
2015-02-02 | 2014-12-31 | 0.73 | 0.74 | 0.01 | 1 | ||
2014-11-03 | 2014-09-30 | 0.69 | 0.84 | 0.15 | 21 | ||
2014-08-06 | 2014-06-30 | 0.67 | 0.51 | -0.16 | 23 | ||
2014-06-02 | 2014-03-31 | 0.7 | 0.95 | 0.25 | 35 | ||
2014-02-03 | 2013-12-31 | 0.62 | 0.48 | -0.14 | 22 | ||
2013-11-05 | 2013-09-30 | 0.64 | 0.54 | -0.1 | 15 | ||
2013-08-06 | 2013-06-30 | 0.61 | 0.52 | -0.09 | 14 | ||
2013-05-29 | 2013-03-31 | 0.59 | 0.71 | 0.12 | 20 | ||
2013-02-05 | 2012-12-31 | 0.67 | 0.53 | -0.14 | 20 | ||
2012-11-08 | 2012-09-30 | 0.67 | 0.64 | -0.03 | 4 | ||
2012-08-09 | 2012-06-30 | 0.61 | 0.59 | -0.02 | 3 | ||
2012-05-23 | 2012-03-31 | 0.74 | 0.69 | -0.05 | 6 |
Mesa Laboratories Corporate Management
| Peter Dansky | Pres Genomics | Profile | |
| Brian Archbold | Senior Improvement | Profile | |
| Bryan Leo | VP Operations | Profile | |
| Garrett Krushefski | VP Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesa Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesa Laboratories. If investors know Mesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesa Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.875 | Dividend Share 0.64 | Earnings Share (46.32) | Revenue Per Share | Quarterly Revenue Growth 0.175 |
The market value of Mesa Laboratories is measured differently than its book value, which is the value of Mesa that is recorded on the company's balance sheet. Investors also form their own opinion of Mesa Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Mesa Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesa Laboratories' market value can be influenced by many factors that don't directly affect Mesa Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesa Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesa Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesa Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.